Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carelizumab combined with concurrent chemoradiotherapy for stage IVB cervical cancer
ChiCTR2000031079Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Cervical Cancer (CC), sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2000031079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031079.